We are raising our 2023 revenue guidance to $435M – $455M ," said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.Clinical Development
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics initiated with a Market Perform at SVB Securities
- Largest borrow rate increases among liquid names
- Corcept Therapeutics Announces Final Results of Tender Offer
